Drugs / HGT-1111
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00681811 | Feb 2008 → Oct 2010 | metachromatic leukodystrophy, late infantile form | Shire | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HGT-1111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00681811 ↗ |
| Modality | Protein / enzyme biologic | “This phase 1/2 study evaluated the safety and efficacy of intravenous (IV) recombinant human ASA (rhASA; HGT-1111, previously known as Metazym) in children with MLD.” PMID 33332761 ↗ Dec 2020 |
| Route | Intravenous | “intravenous (IV) recombinant human ASA” PMID 33332761 ↗ Dec 2020 |